Close X
Attorney Spotlight

What emerging trend in shareholder litigation does Britt Latham find most interesting in his practice today?    Find out more>


Close X


Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more

Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Bass, Berry & Sims Named Finalist in 12 Categories for 17th Annual M&A Advisor Awards

September 10, 2018
M&A Advisor Finalist 2018

Nashville, Tenn., (September 10, 2018) – The M&A Advisor is pleased to announce the finalists of the 17th Annual M&A Advisor Awards. Bass, Berry & Sims had four separate deals recognized as a Finalist among the following 12 categories: 

Acquisition of Paragon Medical, Inc. by NN, Inc.

  • Healthcare & Life Sciences Deal of the Year (Over $100MM-$1B)
  • Industrials Deal of the Year (Over $100MM)

Sale of Medical Transportation Business of Envision Healthcare to KKR

  • Healthcare & Life Sciences Deal of the Year (Over $1B)
  • Corporate/Strategic Deal of the Year (Over $1B)
  • Private Equity Deal of the Deal (Over $1B)
  • M&A Deal of the Year ($1B-$10B)

Sale of New Mountain Capital-Backed MSD to McKesson Corporation

  • Corporate/Strategic Deal of the Year ($500MM-$1B)
  • Private Equity Deal of the Year ($500MM-$1B)
  • M&A Deal of the Year ($500MM-$1B)

Restructuring of Arcadia Services

  • Healthcare & Life Sciences Deal of the Year (Under $100MM)
  • Restructuring Deal of the Year (Under $100MM)
  • M&A Deal of the Year ($10MM-$25MM)

The Finalists have been selected from the nominees in the first stage of evaluation. An independent panel of judges will select the ultimate award winners in each category to be announced at the 17th Annual M&A Advisor Awards Gala to be held in New York City on November 6. Held in conjunction with the Annual M&A Advisor Summit, the Gala will bring together the industry's leaders to celebrate the Finalists and Winners. A full list of the Finalists can be found on the M&A Advisor website.

The M&A Advisor
The M&A Advisor was founded in 1998 to offer insights and intelligence on M&A activities. Over the past 20 years The M&A Advisor has established the premier global network of M&A, Turnaround and Finance professionals. To learn more visit

About Bass, Berry & Sims PLC
With more than 280 attorneys representing numerous publicly traded companies and Fortune 500 businesses, Bass, Berry & Sims has been involved in some of the largest and most significant litigation, investigations, and business transactions in the country. For more information, visit

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.